Morgan Stanley’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,896
| Closed | -$36.8K | – | 8338 |
|
|
2024
Q4 | $36.8K | Buy |
1,896
+1,589
| +518% | +$29.5K | ﹤0.01% | 6384 |
|
|
2024
Q3 | $4.81K | Sell |
307
-56
| -15% | -$498 | ﹤0.01% | 6926 |
|
|
2024
Q2 | $3.07K | Buy |
363
+73
| +25% | +$854 | ﹤0.01% | 6977 |
|
|
2024
Q1 | $4.48K | Sell |
290
-292
| -50% | -$4.45K | ﹤0.01% | 6917 |
|
|
2023
Q4 | $8.04K | Buy |
582
+120
| +26% | +$1.42K | ﹤0.01% | 6886 |
|
|
2023
Q3 | $5.28K | Sell |
462
-1,716
| -79% | -$31.9K | ﹤0.01% | 6906 |
|
|
2023
Q2 | $54.2K | Sell |
2,178
-653
| -23% | -$19.1K | ﹤0.01% | 6178 |
|
|
2023
Q1 | $103K | Sell |
2,831
-800
| -22% | -$49K | ﹤0.01% | 5992 |
|
|
2022
Q4 | $219K | Buy |
3,631
+220
| +6% | +$14.7K | ﹤0.01% | 5630 |
|
|
2022
Q3 | $256K | Buy |
3,411
+660
| +24% | +$69K | ﹤0.01% | 5608 |
|
|
2022
Q2 | $315K | Buy |
2,751
+1,032
| +60% | +$121K | ﹤0.01% | 5658 |
|
|
2022
Q1 | $326K | Buy |
1,719
+1,172
| +214% | +$271K | ﹤0.01% | 5642 |
|
|
2021
Q4 | $189K | Buy |
547
+361
| +194% | +$140K | ﹤0.01% | 6109 |
|
|
2021
Q3 | $62K | Buy |
186
+185
| +18,500% | +$94.9K | ﹤0.01% | 6624 |
|
|
2021
Q2 | $1K | Buy |
+1
| New | +$775 | ﹤0.01% | 7649 |
|
Morgan Stanley's OMIC Position: Q1 2025 in Review
Morgan Stanley sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 1,896 shares — an estimated $36.8K sold.
Morgan Stanley first reported a position in OMIC in Q2 2021 and held it in 15 quarters. The position peaked at $326K in Q1 2022. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.
- Morgan Stanley reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Morgan Stanley sold 1,896 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $36.8K.
- Morgan Stanley first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
- Morgan Stanley's Singular Genomics Systems, Inc. Common Stock position peaked at $326K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.
Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.